Rubicon Research Ltd. benchmarking: Perfomance to industry peers

Financial

	Rubicon Research	Sun Pharma Inds.	Aurobindo Pharma
Operational Metrics
Pharmaceuticals
Number of ANDA's Filed in USA	72.0 .	661.0 .	876.0 .
Number of ANDA's Approved	5.0 .	n/a	n/a
Unclassified
R&D as a % of Total Sales	10.42 %	6.5 %	5.0 %
Financials
5 yr Average ROE	5.76 %	11.67 %	12.72 %
5yr average Equity Multiplier	2.29	1.33	1.46
5yr Average Asset Turnover Ratio	0.66	0.57	0.68
5yr Avg Net Profit Margin	1.04 %	15.4 %	12.5 %
Price to Book	17.23	5.02	1.95
P/E	83.01	35.81	19.94
5yr Avg Cash Conversion Cycle	-23.11 Days	-46.88 Days	-46.37 Days
Inventory Days	96.45 Days	65.22 Days	59.62 Days
Days Receivable	88.85 Days	84.33 Days	30.33 Days
Days Payable	228.02 Days	175.41 Days	121.28 Days
5yr Average Interest Coverage Ratio	2.59	44.12	43.54
5yr Avg ROCE	12.78 %	18.0 %	15.27 %
5yr Avg Operating Profit Margin	11.87 %	26.44 %	19.22 %
5 yr average Debt to Equity	0.74	0.06	0.19
5yr CAGR Net Profit	34.36 %	30.35 %	-8.16 %
5yr Average Return on Assets	1.79 %	8.92 %	8.64 %
Shareholdings
Promoter Holding	59.99 %	54.48 %	51.82 %
Share Pledged by Promoters	0.0	0.97 %	17.5 %
Change in Promoter Holding (3 Yrs)	0.0	0.0	-0.01 %
Change in Mutual Fund Holding (3 Yrs)	0.98 %	-0.37 %	12.02 %

	Rubicon Research	Sun Pharma Inds.	Aurobindo Pharma
Product Wise Break-Up	Product Wise Break-Up Sale of pharmaceutical goods 98.15 Export benefits, royalty etc. 1.77 Income from research services 0.08 ROW 0 India Branded Generics 0 API & Others 0 Emerging Markets 0 US Formulations 0 API 0 Formulations 0	Product Wise Break-Up Active Pharmaceutical Ingredient (API) 4.0 US Formulations 29.0 Emerging Market 19.0 API 0 Sale of pharmaceutical goods 0 India Branded Generics 34.0 Export benefits, royalty etc. 0 Formulations 0 Income from research services 0 Western Europe & Other Markets 14.0	Product Wise Break-Up API & Others 0 US Formulations 0 Emerging Markets 0 Active Pharmaceutical Ingredient (API) 11.64 Sale of pharmaceutical goods 0 India Branded Generics 0 Export benefits, royalty etc. 0 Formulations 88.36 Income from research services 0 ROW 0
Location Wise Break-Up	Location Wise Break-Up USA 99.5 India 0.32 Rest of the World 0 Emerging Markets 0 Europe 0 Others 0.18	Location Wise Break-Up Europe 0 Rest of the World 14.8 USA 32.68 India 33.39 Emerging Market 19.13	Location Wise Break-Up Europe 29.7 Rest of the World 17.0 USA 44.3 India 9.0 Emerging Markets 0
Therapeutic Area Break-Up	Therapeutic Area Break-Up Others 100	-	-
Customer Wise Break-Up	Customer Wise Break-Up Others 100	-	-
Asset Break-Up - Geography Wise	Asset Break-Up - Geography Wise Others 100	-	-